Select publications

Aus G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7- year follow-up of a randomized controlled trial. BJU Int 2002;90(6):561-6. Abstract

Gleave ME et al; Canadian Uro-Oncology Group. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 2001;166(2):500-6. Abstract

Petrylak DP. Future directions in the treatment of androgen-independent prostate cancer. Urology 2005;65(6 Suppl):8-12. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20.Abstract

Petrylak DP et al. SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA). Presentation. ASCO 2004b;Abstract 3.

Peyromaure M et al. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: Long-term experience. Urology 2005;65(4):724-9. Abstract

Propotnich D et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003:43(3):233-9. Abstract

Rashid MH, Chaudbury UB. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 2004;9(3):295-301. Abstract

Schulman CC et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000;38(6):706-13. Abstract

Soloway MS et al; Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167(1):112-6. Abstract